Rocket Pharmaceuticals, Inc.
(NASDAQ : ITEK)

( )
ITEK After-Hours: () as of PM
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield

Message Boards

...

News

...
Health Technology » Biotechnology

Company Profile

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The company's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. It also develops an AAV-based gene therapy program for an undisclosed rare pediatric disease. The company was founded in 1999 and is headquartered in New York, NY.